laboratori corpor america hold
usd apr pm et
summari clinic laboratori organ offer broad rang test servic
nation network laboratori
price-to-earnings oper ep
risk assess reflect lh leadership posit
larg matur industri broad geograph servic area
client state divers balanc
payer mix howev note uncertainti
surround reimburs rate futur regul
present modest risk compani
jul ep estim base cfra oper earn
histor earn report compani report
cash dividend paid last year
past perform indic futur perform reli upon
analysi prepar equiti analyst
apr pm stock trade
anticip sale grow
billion growth
acquisit divestitur activ
net posit impact revenu growth
expect yoy improv
diagnost covanc drug
develop cdd segment support
higher growth expect diagnost
revenu grow
includ neg reimburs pressur
cdd segment grow
reimburs cut
protect access medicar act pama
sustain headwind clinic laboratori
test continu pressur
margin revenu lab test
compani howev dynam could
ultim benefit lh mani hospit
independ lab competitor shut
price pressur
contract basi point
reimburs pressur continu
outweigh save lh launchpad
optim initi synergi
long-term margin growth could come
higher esoter test volum lab
think risk reward lh
trade forward earn properli
reflect valuat larg lab provid
 lh sustain competit
advantag due scale abil provid
wide varieti test yet lab provid face
incess price pressur face
pressur recent year lh diagnost
busi demonstr consist low
organ growth off-set impact price
declin lh boost test
volum acquir hospit lab smaller
lab compani succumb
reimburs pressur expect lh
continu make acquisit price
pressur continu lh also need stay
top optim effort compani
maintain margin face industri
risk recommend target price
opportun acquir small lab
worse-than-expect margin price
target base
vs lh three-year rang
ep
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
laboratori corpor america hold
laboratori director
execut vice-president chief
corpor overview laboratori corpor america lh one two largest independ
 clinic laboratori clinic laboratori test use medic profession routin test
patient diagnosi monitor treatment diseas lh provid comprehens clinic
laboratori end-to-end drug develop servic two busi segment labcorp
diagnost lcd covanc drug develop cdd lh provid servic broad rang
custom primari custom group serv lh manag care organ health
insur biopharmaceut medic devic diagnost compani physician health
care provid hospit health system
compani lcd segment focus test bodili fluid human tissu lh offer nearli
differ test consist routin test specialti test refer esoter
frequent administ routin test includ blood chemistri analys urinalysi blood cell count
thyroid test pap test hemoglobin test compani esoter test includ test
infecti diseas allergi diagnost genet ident oncolog compani provid
diagnost drug develop technology-en solut million patient
cdd segment provid end-to-end drug develop medic devic companion diagnost
develop solut early-stag research clinic develop commerci market access
drug develop servic compani like cdd commonli refer contract research
organ compani support clinic trial activ approxim countri
central laboratori preclin clinic develop busi gener safeti efficaci
data support drug approv compani cdd busi collabor
yoy novel drug approv food drug administr fda
includ novel oncolog drug rare orphan diseas drug addit
cdd involv develop current top drug market measur
corpor strategi lh aim expand role health care focus key strateg initi
support custom transit value-bas care streamlin drug develop process
creat lead differenti consum experi respons grow import
consum health care lh focus facilit differenti consum experi
invest heavili new tool technolog servic addit lh believ continu
consolid healthcar compani strong relationship hospit health system
allow one largest provid laboratori test servic provid lead solut help
improv patient outcom reduc health care cost health system increasingli becom focal
point coordin patient care
protect access medicar act pama reimburs test price could cut
maximum laboratori access
beneficiari lab act enact decemb delay implement new clf
clinic laboratori fee schedul rate reimburs rate cut
maximum amount result net reduct lh reimburs revenu approxim
million expect cut similar increment neg impact lh pama reimburs
cut disproportion affect small lab creat attract acquisit opportun lh
think opportunist lab acquisit key driver lh growth next year
competit landscap lh estim clinic laboratori test industri gener
revenu approxim billion clinic laboratori industri consist primarili three
type provid hospital-bas laboratori physician-offic laboratori independ clinic
anatom patholog laboratori oper lcd clinic laboratori busi
intens competit center medicar medicaid servic depart
human servic hh estim approxim
hospital-bas laboratori approxim physician-offic laboratori
independ clinic laboratori lcd compet laboratori believ
compani largest competitor also publicli trade
signific consolid past decad industri
competitor cro industri rang hundr smaller limit number larg
global capabl cdd main competit consist small larg well
in-hous depart biopharmaceut compani lesser extent select univers
financi trend revenu increas year-over-year billion repres
five-year compound annual growth rate compound-annual-growth-rate sale growth aid significantli
recent year acquisit numer smaller lab exampl revenu growth due
acquisit organ growth effect less pronounc revenu
growth due acquisit adjust ep increas year-over-year
reflect five-year compound-annual-growth-rate decemb compani elev net debt
capit ratio moder net debt trailing-twelve-month ebitda ratio
redistribut reproduct prohibit without prior written permiss copyright cfra
laboratori corpor america hold
base cfra proprietari quantit model
stock rank overvalu
analysi stock current worth base
cfra proprietari quantit model suggest
lh slightli overvalu usd
bullish sinc april technic indic lh
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
laboratori corpor america hold
outlook health care servic
sub-industri next year neg
recess concern
impact expect demand typic health care
servic declin significantli yoy
peopl stay home health care
system focu shift address
exampl comment late march
anesthesiolog busi experienc
signific declin elect surgeri
volum driven closur oper
suit facil yet
opportun exampl lab
test provid labcorp quest
relat test
long term even weak macroeconom
condit persist expect demand health
care servic remain rel steadi
compar industri
import health care consum prior
profit health care
servic compani pressur recent
year factor rise wage labor
legislative/regulatori initi
difficult determin rise unemploy
relat effect affect
pressur
believ long-term trend rise
health care spend
incentiv legisl regul
find way control cost health care
servic industri easi target
cost cut exampl initi lower
health care cost includ trump initi
chang payment model dialysi treatment
bipartisan effort tackl surpris bill
unclear chang dialysi
payment affect firm like
long run believ surpris bill
legisl like neg impact
physician outsourc group mednax
limit physician reimburs
struck individu mandat
associ afford act
howev court avoid determin
much remain valid believ
outcom remov possibl
worst-cas scenario health care servic
firm complet
gener benefit increas
insur coverag past sever year
elimin certain provis
could neg impact
industri earli suprem court
agre hear case decis
case like made
earliest believ suprem
court allow remain
minim impact health care
prior anticip
sub-industri ep growth
estim growth rate given
fluiditi volatil current
situat await earn commentari
updat ep expect health
march
declin composit index
 health servic index
gain vs increas
base index
five-year market price perform apr
note sector sub-industri inform base
past perform indic futur perform
reli upon
laboratori corpor america
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
laboratori corpor america hold
america hold rais price target base
multipl lh three-year averag ep
ep vs lower estim initi ep
revenu billion increas larg driven
organ growth lh adjust oper margin
lower price tie implement pama
busi disposit higher personnel cost partial offset
headwind launchpad busi improv initi sale
labcorp diagnost segment declin year-over-year covanc
drug develop segment achiev growth revenu
diagnost test price continu neg impact second
round pama price cut yet present lh opportun acquir smaller
fail lab februari board author repurchas billion
stock /kevin huang cfa
corpor america lower price target
base ep estim lh like
primari competitor lower revenu
earn outlook late novemb lh guid investor
toward adjust ep vs previou rang
lh revis outlook due lower-than-expect volum growth
result slower growth refer direct-to-consum genet test
lower referr volum hospit health system volum declin
upcom loss certain manag care plan advers weather lower
ep ep
expect sale growth compar prior estim
analyst research note compani news
pm et cfra maintain hold opinion share laboratori corpor
america lift target price base
multipl vs lh rang next
ep ep vs higher
estim lower ep commenc ep
revenu grew billion slightli ahead expect
revenu growth due growth acquisit organ
growth off-set partial busi disposit foreign
currenc translat diagnost busi grew yoy
billion revenu per requisit exclud impact divestitur
increas test requisit volum increas came
acquisit revenu covanc drug develop busi cdd
increas yoy billion lh outlook midpoint
roughli in-lin consensu expect revenu slightli
earn slightli expect /kevin huang cfa
pm et cfra keep hold opinion share laboratori corpor
america lift target price base
multipl ep ep vs
exceed estim rais ep
ep revenu grew billion
fuel acquisition-rel growth organ growth off-set
partial busi disposit foreign currenc translat
diagnost busi revenu per requisit exclud impact
divestitur increas despit neg impact
reimburs cut test requisit volum increas come
acquisit revenu covanc drug develop busi cdd
increas yoy billion howev cdd organ growth fell
bp short expect encourag hear lh remain
track launchpad initi help lh maintain
pm et cfra reiter hold opinion share laboratori
corpor america lift target price
base multipl lh averag ep
estim ep vs beat estim
rais ep maintain ep
revenu grew billion exclud disposit
busi revenu grew roughli line expect
diagnost busi revenu per requisit exclud impact
divestitur increas despit neg impact
reimburs cut relat protect access medicar act pama
test requisit volum declin organ much
wors key competitor organ volum growth organ sale
growth covanc drug develop busi weaker
expect lh adjust oper margin declin
prior-year period larg due pama /kevin huang cfa
pm et cfra maintain hold opinion share laboratori corpor
america lift target price base
multipl lh averag ep estim
lift ep lower ep
ep vs lower estim
revenu billion billion prior-year period
primarili divestitur unfavor currenc translat
organ basi revenu grew diagnost busi revenu per
requisit exclud impact divestitur decreas
better-than-expect due favor mix organ sale growth
covanc drug develop busi cdd expect
larg pass-through revenu year-over-year quarter
exclud pass-through revenu organ revenu growth cdd in-lin
compani full year guidanc rang /kevin huang cfa
pm et cfra keep hold opinion share laboratori corpor
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
laboratori corpor america hold
fiscal year analyst estim lh earn
usd quarter fiscal year lh
announc earn per share usd
repres total revenu estim
fiscal year analyst estim lh earn per
share grow usd
total
estimate estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
laboratori corpor america hold
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
redistribut reproduct prohibit without prior written permiss copyright cfra
laboratori corpor america hold
content includ rate credit-rel analys data valuat model softwar
applic output therefrom part thereof content may modifi
revers engin reproduc distribut form mean store
databas retriev system without prior written permiss cfra content shall
use unlaw unauthor purpos cfra third-parti provid
well director offic sharehold employe agent guarante
accuraci complet timeli avail content
past perform necessarili indic futur result
document may contain forward-look statement forecast forecast
reliabl indic futur perform
report intend constitut offer solicit buy sell
secur engag invest activ report inform purpos
recommend report made respect particular investor
type investor secur financi instrument strategi mention herein may
suitabl investor materi intend specif investor
take account investor particular invest object financi situat
need act recommend materi consid whether
suitabl particular circumst necessari seek profession advic
cfra may licens certain intellectu properti provid servic otherwis
busi relationship certain issuer secur subject cfra
research report includ exchange-trad invest whose invest object
substanti replic return proprietari index cfra case cfra
paid fee tie amount asset invest fund volum trade
activ fund invest fund may result cfra receiv compens
addit subscript fee compens servic render cfra
howev part cfra compens servic tie recommend
rate addit inform subject compani may avail upon request
cfra financi data provid global market intellig document contain
global industri classif standard gic develop and/or exclus
properti inc global market intellig gic servic mark
 global market intellig licens use cfra
disclaim notic
certain inform report provid global inc and/or affili
subsidiari collect global inform subject follow
disclaim notic copyright global market intellig affili
applic right reserv noth contain herein invest advic
refer particular invest secur credit rate observ
concern secur invest provid recommend buy
sell hold invest secur make invest decis may
contain inform obtain third parti includ rate credit rate
agenc reproduct distribut inform third parti content
form prohibit except prior written permiss global
relat third parti applic neither third parti provid guarante
accuraci complet timeli avail inform includ rate
respons error omiss neglig otherwis regardless
caus result obtain use inform content
includ rate credit rate statement opinion statement
fact recommend purchas hold sell secur address
suitabl secur suitabl secur invest purpos
reli invest advic
